POMDOCTOR Ltd (POM) Form 6-K — Oct 2, 2026
POMDOCTOR Limited shareholders approved at a September 30, 2026 extraordinary general meeting the termination of the company's ADR program and the direct listing of its Class A ordinary shares on Nasdaq, both to occur on the same date. Shareholders also approved a 10-to-1 share consolidation, with every ten shares of US$0.0001 par value consolidated into one share of US$0.001 par value, effective simultaneously with the ADR termination and listing; authorized share capital is restructured from 500,000,000 to 50,000,000 shares.
Key figures
- Proposal1 for
- 45395656
- Proposal2 for
- 45387346
- Proposal1 against
- 34398
- Proposal2 against
- 39999
- Reverse split ratio
- 10:1
- New authorized shares
- 50000000
- Shares outstanding pre
- 27802964
- Prior authorized shares
- 500000000
- Aggregate votes outstanding
- 66601762
- Class a shares outstanding pre
- 25760922
- Class b shares outstanding pre
- 2042042
- Discretionary proxies excluded
- 7639947
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.